Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Author information

1
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.
2
University of Michigan Rogel Cancer Center.
3
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
4
Moffitt Cancer Center.
5
Dana-Farber/Brigham and Women's Cancer Center.
6
City of Hope National Medical Center.
7
O'Neal Comprehensive Cancer Center at UAB.
8
Yale Cancer Center/Smilow Cancer Hospital.
9
Patient Advocate.
10
Roswell Park Comprehensive Cancer Center.
11
Massachusetts General Hospital Cancer Center.
12
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
13
Fred & Pamela Buffett Cancer Center.
14
Abramson Cancer Center at the University of Pennsylvania.
15
Huntsman Cancer Institute at the University of Utah.
16
Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
17
Fox Chase Cancer Center.
18
Vanderbilt-Ingram Cancer Center.
19
UC San Diego Moores Cancer Center.
20
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
21
Stanford Cancer Institute.
22
Mayo Clinic Cancer Center.
23
Memorial Sloan Kettering Cancer Center.
24
Duke Cancer Institute.
25
The University of Texas MD Anderson Cancer Center.
26
University of Colorado Cancer Center; and.
27
National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor-related diarrhea/colitis and cardiovascular irAEs.

PMID:
32135517
DOI:
10.6004/jnccn.2020.0012

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center